Growth factor receptors in breast cancer: Potential for therapeutic intervention

Oncologist

Volumn 8, Issue 1, 2003, Pages 5-17

  Nahta, Rita ^a   Hortobágyi, Gabriel N ^a   Esteva, Francisco J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biologic therapy; Breast neoplasm; EGFR; HER2; IGF IR; Monoclonal antibodies; Prognostic markers; Tyrosine kinase inhibitors

Indexed keywords

CANERTINIB; CETUXIMAB; E1A; EPIDERMAL GROWTH FACTOR 2; EPIDERMAL GROWTH FACTOR 3; EPIDERMAL GROWTH FACTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN; ESTROGEN RECEPTOR; GEFITINIB; GROWTH FACTOR RECEPTOR; HUMAN MOUSE ANTIBODY; IMATINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E1A; NEU DIFFERENTIATION FACTOR; PANITUMUMAB; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; STEM CELL FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL THERAPY; BREAST CANCER; CLINICAL TRIAL; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR BLOCKING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, GROWTH FACTOR;

EID: 0037285971     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-1-5     Document Type: Article

References (157)

1. Atkins JH, Gershell LJ. Selective anticancer drugs. Nat Rev Drug Discov 2002;1:491-492.
2. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998;4:527-534.
3. Cohen S, Taylor JM. Epidermal growth factor: chemical and biological characterization. Recent Prog Horm Res 1974;30:533-550.
4. Taylor JM, Mitchell WM, Cohen S. Characterization of the binding protein for epidermal growth factor. J Biol Chem 1974;249:2188-2194.
5. Taylor JM, Mitchell WM, Cohen S. Characterization of the high molecular weight form of epidermal growth factor. J Biol Chem 1974;249:3198-3203.
6. Downward J, Yarden Y, Mayes E et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984;307:521-527.
7. Lin CR, Chen WS, Kruiger W et al. Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science 1984;224:843-848.
8. Ullrich A, Coussens L, Hayflick JS et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309:418-425.
9. Cooper JA, Hunter T. Similarities and differences between the effects of epidermal growth factor and Rous sarcoma virus. J Cell Biol 1981;91:878-883.
10. Chinkers M, Cohen S. Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein. Nature 1981;290:516-519.
11. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19(suppl 18):32S-40S.
12. Fan Z, Lu Y, Wu X et al. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994;269:27595-27602.
13. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-513.
14. Tortora G, Caputo R, Pomatico G et al. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin Cancer Res 1999;5:875-881.
15. Masui H, Kawamoto T, Sato JD et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44:1002-1007.
16. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001;37(suppl 4):S16-S22.
17. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-1611.
18. Mendez MJ, Green LL, Corvalan JR et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997;15:146-156.
19. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002;29(suppl 4):47-50.
20. Yang XD, Jia XC, Corvalan JR et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-1243.
21. Yang XD, Jia XC, Corvalan JR et al. Development of ABXEGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23.
22. Allen LF, Lenehan PF, Eiseman IA et al. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002;29(suppl 11):11-21.
23. Slichenmyer WJ, Fry DW. Anticancer therapy targeting the ErbB family of receptor tyrosine kinases. Semin Oncol 2001;28(suppl 16):67-79.
24. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001;13:491-498.
25. Elsayed YA, Sausville EA. Selected novel anticancer treatments targeting cell signaling proteins. The Oncologist 2001;6:517-537.
26. Swaisland H, Laight A, Stafford L et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001;40:297-306.
27. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-2250.
28. Baselga J, Yano S, Giaccone G et al. Initial results from a phase II trial of ZD1839 (Iressa) as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1). Clin Cancer Res 2001;7:3780.
29. Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 2002;29:4-10.
30. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279.
31. Rusnak DW, Affleck K, Cockerill SG et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001;61:7196-7203.
32. Padhy LC, Shih C, Cowing D et al. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982;28:865-871.
33. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-230.
34. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986;45:649-657.
35. Schechter AL, Stern DF, Vaidyanathan L et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984;312:513-516.
36. Coussens L, Yang-Feng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
37. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-976.
38. Yamamoto T, Ikawa S, Akiyama T et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986;319:230-234.
39. Di Fiore PP, Pierce JH, Kraus MH et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-182.
40. Guy CT, Webster MA, Schaller M et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992;89:10578-10582.
41. Guy CT, Cardiff RD, Muller WJ. Activated neu induces rapid tumor progression. J Biol Chem 1996;271:7673-7678.
42. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987;235:177-182.
43. Esteva-Lorenzo FJ, Sastry L, King CR. The erbB-2 gene: from research to application. In: Dickson RB, Salomon DS, eds. Hormones and Growth Factors in Development and Neoplasia. New York: John Wiley & Sons, 1998:421-444.
44. Tsuda H, Hirohashi S, Shimosato Y et al. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 1990;81:327-332.
45. Paik S, Hazan R, Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-112.
46. Lovekin C, Ellis IO, Locker A et al. C-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-443.
47. McCann AH, Dervan PA, O'Regan M et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991;51:3296-3303.
48. Isola JJ, Holli K, Oksa H et al. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994;73:652-658.
49. Horiguchi J, Iino Y, Takei H et al. Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. Oncology 1994;51:47-51.
50. Thor AD, Berry DA, Budman DR et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-1360.
51. Paik S, Bryant J, Park C et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-1370.
52. Bianco AR, De Laurentiis M, Carlomagno C et al. HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): complete data at 20 yr of the Naples GUN randomized trial. Proc Am Soc Clin Oncol 2000;19:289a.
53. Bacus SS, Gudkov AV, Esteva FJ et al. Expression of erb-B receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. Breast Dis 2000;11:63-75.
54. Esteva FJ, Pusztai L, Symmans WF et al. Clinical relevance of HER-2 amplification and overexpression in human cancers. Ref Gynecol Obst 2000;7:267-276.
55. Pusztai L, Esteva FJ, Cristofanilli M et al. Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer Treat Rev 1999;25:271-277.
56. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-962.
57. -) metastatic breast cancer. Breast Cancer Res Treat 1999;57:17a.
58. Niehans GA, Singleton TP, Dykoski D et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993;85:1230-1235.
59. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 1987;84:7159-7163.
60. Park JW, Stagg R, Lewis GD et al. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treat Res 1992;61:193-211.
61. Hurwitz E, Stancovski I, Sela M et al. Suppression and promotion of tumor growth by monoclonal antibodies to erbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA 1995;92:3353-3357.
62. Kasprzyk PG, Song SU, Di Fiore PP et al. Therapy of an animal model of human gastric cancer using a combination of antierbB-2 monoclonal antibodies. Cancer Res 1992;52:2771-2776.
63. Harwerth IM, Wels W, Schlegel J et al. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993;68:1140-1145.
64. Xu F, Lupu R, Rodriguez GC et al. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 1993;53:401-408.
65. Pietras RJ, Fendly BM, Chazin VR et al. Antibody to HER2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-1838.
66. Pegram MD, Finn RS, Arzoo K et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537-547.
67. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.
68. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
69. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
70. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
71. Livingston RB, Esteva FJ. Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug? The Oncologist 2001;6:315-316.
72. Fornier M, Esteva FJ, Seidman A. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Onco1 2000;27(suppl 11):38-45; discussion 92-100.
73. Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671.
74. Seidman AD, Fornier M, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
75. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808.
76. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-2730.
77. O'Shaughnessy JA, Vukelja S, Marsland T et al. Gemcitabine and trastuzumab for HER-2 positive metastatic breast cancer: preliminary results of a phase II study. Breast Cancer Res Treat 2001;69:302a.
78. Pegram MD, Lopez A, Konecny G et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000;27(suppl 11):21-25;92-100.
79. Konecny G, Untch M, Slamon D et al. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Res Treat 2001;67:223-233.
80. Nabholtz JM. Preliminary results of two open-label multicenter pilot phase II trials with Herceptin in combination with docetaxel and platinum salts (cis- or carboplatin) (TCH) as therapy for advanced breast cancer in women with overexpressing HER2/neu. Breast Cancer Res Treat 2000;58:327a.
81. Slamon DJ, Patel R, Northfelt R et al. Phase II pilot study of Herceptin combined with Taxotere and carboplatin in metastatic breast cancer patients overexpressing the HER2-neu proto-oncogene: a pilot study of the UCLA Network. Proc Am Soc Clin Oncol 2001;20:193a.
82. Mass RD, Press M, Anderson S et al. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 2001;20:85a.
83. Roche PC, Suman VJ, Jenkins RB et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-857.
84. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854.
85. Batra JK, Kasprzyk PG, Bird RE et al. Recombinant antierbB-2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 1992;89:5867-5871.
86. Wels W, Harwerth IM, Mueller M et al. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 1992;52:6310-6317.
87. King CR, Fischer PH, Rando RF et al. The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. Semin Cancer Biol 1996;7:79-86.
88. King CR, Kasprzyk PG, Fischer PH et al. Preclinical testing of an anti-erbB-2 recombinant toxin. Breast Cancer Res Treat 1996;38:19-25.
89. Reiter Y, Pai LH, Brinkmann U et al. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res 1994;54:2714-2718.
90. Smellie WJ, Dean CJ, Sacks NP et al. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl) benzoate radioiodination methods. Cancer Res 1995;55(suppl 23):5842s-5846s.
91. Allan SM, Dean C, Fernando I et al. Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen. Br J Cancer 1993;67:706-712.
92. Weiner LM, Holmes M, Adams GP et al. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 1993;53:94-100.
93. Weiner LM, Holmes M, Richeson A et al. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol 1993;151:2877-2886.
94. Shalaby MR, Carter P, Maneval D et al. Bispecific HER2 × CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice. Clin Immunol Immunopathol 1995;74:185-192.
95. Weiner LM, Clark JI, Davey M et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 1995;55:4586-4593.
96. Yu D, Shi D, Scanlon M et al. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. Cancer Res 1993;53:5784-5790.
97. Yu D, Matin A, Xia W et al. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER2/neu. Oncogene 1995;11:1383-1388.
98. Hortobagyi GN, Ueno NT, Xia WY et al. Cationic liposomemediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001;19:3422-3433.
99. Bertram J, Killian M, Brysch W et al. Reduction of erbB2 gene product in mammary carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides. Biochem Biophys Res Commun 1994;200:661-667.
100. Colomer R, Lupu R, Bacus SS et al. ErbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 1994;70:819-825.
101. Disis ML, Bernhard H, Gralow JR et al. Immunity to the HER-2/neu oncogenic protein. Ciba Found Symp 1994;187:198-207; discussion 207-211.
102. Disis ML, Smith JW, Murphy AE et al. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 1994;54:1071-1076.
103. Disis ML, Calenoff E, McLaughlin G et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
104. Yoshino I, Goedegebuure PS, Peoples GE et al. HER2/neu-derived peptides are shared antigens among human nonsmall cell lung cancer and ovarian cancer. Cancer Res 1994;54:3387-3390.
105. Peoples GE, Smith RC, Linehan DC et al. Shared T cell epitopes in epithelial tumors. Cell Immunol 1995;164:279-286.
106. Druker BJ. STI571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol Med 2002;8:S14-S18.
107. Druker B. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. Semin Hematol 2001;38(suppl 8):9-14.
108. Mauro MJ, O'Dwyer M, Heinrich MC et al. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20:325-334.
109. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
110. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
111. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
112. Apperley JF, Gardembas M, Melo JV et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
113. Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-3591.
114. DiPaola RS, Kuczynski WI, Onodera K et al. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Therapy 1997;4:176-182.
115. Yee D. The insulin-like growth factor system as a treatment target in breast cancer. Semin Oncol 2002;29(suppl 11):86-95.
116. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
117. Yu H, Levesque MA, Khosravi MJ et al. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer 1996;74:1242-1247.
118. Hankins GR, De Souza AT, Bentley RC et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996;12:2003-2009.
119. Byrd JC, Devi GR, De Souza AT et al. Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations. J Biol Chem 1999;274:24408-24416.
120. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001;8:197-209.
121. Lu YH, Zi XL, Zhao YH et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-1857.
122. Campbell MJ, Woodside JV, Secker-Walker J et al. IGF status is altered by tamoxifen in patients with breast cancer. Mol Pathol 2001;54:307-310.
123. Torrisi R, Baglietto L, Johansson H et al. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer 2001;85:1838-1841.
124. O'Byrne KJ, Dobbs N, Propper DJ et al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999;79:1413-1418.
125. Ingle JN, Suman VJ, Kardinal CG et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999;85:1284-1292.
126. Dolan JT, Miltenburg DM, Granchi TS et al. Treatment of metastatic breast cancer with somatostatin analogues - a meta-analysis. Ann Surg Oncol 2001;8:227-233.
127. Chernicky CL, Tan H, Yi L et al. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo. Mol Pathol 2002;55:102-109.
128. Kull Jr FC, Jacobs S, Su YF et al. Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem 1983;258:6561-6566.
129. Arteaga CL, Kitten LJ, Coronado EB et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989;84:1418-1423.
130. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989;49:6237-6241.
131. Kato H, Faria TN, Stannard B et al. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem 1993;268:2655-2661.
132. Goodwin PJ, Ennis M, Pritchard KI et al. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 2002;74:65-76.
133. Palmu S, Soderstrom KO, Quazi K et al. Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. Anticancer Res 2002;22:411-414.
134. Hines SJ, Litz JS, Krystal GW. Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors. Breast Cancer Res Treat 1999;58:1-10.
135. Feakins RM, Wells CA, Young KA et al. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast. Hum Pathol 2000;31:1214-1222.
136. Peres R, Betsholtz C, Westermark B et al. Frequent expression of growth factors for mesenchymal cells in human mammary carcinoma cell lines. Cancer Res 1987;47:3425-3429.
137. Yi B, Williams PJ, Niewolna M et al. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 2002;62:917-923.
138. Klijn JG, Berns PM, Schmitz PI et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13:3-17.
139. Knowlden JM, Gee JM, Seery LT et al. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998;17:1949-1957.
140. Tang CK, Concepcion XZ, Milan M et al. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 1999;59:5315-5322.
141. Srinivasan R, Gillett CE, Barnes DM et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 2000;60:1483-1487.
142. Kew TY, Bell JA, Pinder SE et al. c-erbB4 protein expression in human breast cancer. Br J Cancer 2000;82:1163-1170.
143. Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000;5:107-115.
144. 1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res Treat 1999;55:267-283.
145. Baselga J, Norton L, Masui H et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-1333.
146. McClelland RA, Barrow D, Madden TA et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001;142:2776-2788.
147. Moulder SL, Yakes FM, Muthuswamy SK et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-8895.
148. Ciardiello F, Caputo R, Borriello G et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002;98:463-469.
149. Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-2560.
150. Normanno N, Campiglio M, De Luca A et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13:65-72.
151. Chan KC, Knox WF, Gee JM et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 2002;62:122-128.
152. Pollack VA, Savage DM, Baker DA et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291:739-748.
153. Citri A, Alroy I, Lavi S et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 2002;21:2407-2417.
154. Nelson JM, Fry DW. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 2001;276:14842-14847.
155. Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 2000;48:1519-1528.
156. Nahta R, Iglehart JD, Kempkes B et al. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res 2002;62:2267-2271.
157. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137.